MEC Practice Academy 11.19
News|Videos|April 16, 2025

The risks of prescribing GLP-1 drugs: The importance of informed consent

Author(s)Todd Shryock

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1 receptor agonists—such as semaglutide and tirzepatide—are transforming obesity and diabetes care, offering dramatic results in weight loss and blood sugar control. But as demand for these drugs skyrockets, so do concerns about the legal and clinical risks for prescribing physicians. Medical Economics spoke with Ericka Adler, a health care attorney with Roetzel & Andress to discuss the key issues doctors need to keep in mind when prescribing GLP-1 medications.

From ensuring informed consent to navigating long-term safety data, physicians must strike a careful balance between patient demand and professional responsibility. We discuss common pitfalls, including prescribing without proper documentation and relying on compounding pharmacies. We also look at the evolving regulatory landscape and what that could mean for medical liability.

Whether you're already prescribing GLP-1s or just considering it, this video provides essential guidance to help you protect your practice and your patients. In this episode, Adler discusses the risks of not having proper informed consent.


Related to this article

Sethu Reddy: ©Sethu Reddy
Prior authorization, step therapy and shifting coverage rules keep patients from obesity drugs with proven benefits, an endocrinologist argues — and the long-term savings make the case for broader access.
Is more health care access always better?: ©Yodiyim - stock.adobe.com
In 590,282 California heart attack hospitalizations, a new PCI-capable facility within a 30-minute drive lowered 30-day mortality 20% in communities without prior access but did not change survival where the procedure was already available.
Is late-night eating hurting your liver?: ©Nalidsa - stock.adobe.com
An Oregon Health & Science University-led analysis of nearly 200,000 people found a 20% to 30% higher rate of fatty liver disease and cirrhosis among those who reported eating after dinner or after bedtime.